Management of HCC

https://doi.org/10.1016/S0168-8278(12)60009-9Get rights and content

Summary

Hepatocellular carcinoma (HCC) is a highly prevalent and lethal neoplasia, the management of which has significantly improved during the last few years. A better knowledge of the natural history of the tumor and the development of staging systems that stratify patients according to the characteristics of the tumor, the liver disease, and the performance status, such as the BCLC (Barcelona Clinic Liver Cancer) system, have led to a better prediction of prognosis and to a most appropriate treatment approach. Today curative therapies (resection, transplantation, ablation) can improve survival in patients diagnosed at an early HCC stage and offer a potential long-term cure. Patients with intermediate stage HCC benefit from chemoembolization and those diagnosed at advanced stage benefit from sorafenib, a multikinase inhibitor with antiangiogenic and antiproliferative effects. In this article we review the current management in HCC and the new advances in this field.

References (181)

  • JA Marrero et al.

    Desgamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients

    Hepatology

    (2003)
  • M Capurro et al.

    Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma

    Gastroenterology

    (2003)
  • JA Marrero et al.

    Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma

    Gastroenterology

    (2009)
  • A Sangiovanni et al.

    Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance

    Gastroenterology

    (2004)
  • V Santi et al.

    Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival

    J Hepatol

    (2010)
  • L Di Tommaso et al.

    The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma

    J Hepatol

    (2009)
  • SA Khan et al.

    Changing international trends in mortality rates for liver, biliary and pancreatic tumours

    J Hepatol

    (2002)
  • U Cillo et al.

    Prospective validation of the Barcelona Clinic Liver Cancer staging system

    J Hepatol

    (2006)
  • J Bruix et al.

    Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

    J Hepatol

    (2001)
  • JM Llovet et al.

    Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

    Lancet

    (2002)
  • S Arii et al.

    Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan

    Hepatology

    (2000)
  • M Omata et al.

    Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation

    Gastroenterology

    (2004)
  • S Shiina et al.

    A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma

    Gastroenterology

    (2005)
  • CM Lo et al.

    Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

    Hepatology

    (2002)
  • S Eguchi et al.

    Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey

    Surgery

    (2008)
  • H Imamura et al.

    Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy

    J Hepatol

    (2003)
  • S Roayaie et al.

    A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma

    Gastroenterology

    (2009)
  • G D'Amico et al.

    Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies

    J Hepatol

    (2006)
  • T Ishizawa et al.

    Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma

    Gastroenterology

    (2008)
  • PV Korita et al.

    Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma

    Hum Pathol

    (2008)
  • PP McHugh et al.

    Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma

    HPB (Oxford)

    (2010)
  • B Mínguez et al.

    Gene-expression signature of vascular invasion in hepatocellular carcinoma

    J Hepatol

    (2011)
  • J Ferlay et al.

    Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

    Int J Cancer

    (2010)
  • DY But et al.

    Natural history of hepatitis-related hepatocellular carcinoma

    World J Gastroenterol

    (2008)
  • G Fattovich et al.

    Natural history and prognostic factors for chronic hepatitis type B

    Gut

    (1991)
  • HI Yang et al.

    Hepatitis B e antigen and the risk of hepatocellular carcinoma

    N Engl J Med

    (2002)
  • HI Yang et al.

    Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

    J Clin Oncol

    (2010)
  • GS Qian et al.

    A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China

    Cancer Epidemiol Biomarkers Prev

    (1994)
  • F Degos et al.

    Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death

    Gut

    (2000)
  • J Bruix et al.

    Management of hepatocellular carcinoma: an update

    Hepatology

    (2011)
  • RS O'Shea et al.

    Alcoholic liver disease

    Hepatology

    (2010)
  • EE Calle et al.

    Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults

    N Engl J Med

    (2003)
  • WE Naugler et al.

    Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production

    Science

    (2007)
  • A Singal et al.

    Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis

    Aliment Pharmacol Ther

    (2009)
  • DJ Brenner et al.

    Computed tomography-an increasing source of radiation exposure

    N Engl J Med

    (2007)
  • IC Lee et al.

    Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: a novel role of alpha-fetoprotein

    Liver Int

    (2010)
  • M Miyazawa et al.

    Alpha-fetoprotein-producing clear cell carcinoma of the extrahepatic bile ducts

    J Clin Gastroenterol

    (2006)
  • X Liu et al.

    Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 cases

    J Surg Oncol

    (2010)
  • H Okuda et al.

    Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity

    Cancer

    (1999)
  • BH Zhang et al.

    Randomized controlled trial of screening for hepatocellular carcinoma

    J Cancer Res Clin Oncol

    (2004)
  • Cited by (0)

    View full text